Antihistamine Use in Infants < 2 Years: Evidence‑Based Guideline Summary

Approved Oral Antihistamines

Cetirizine 0.25 mg/kg administered twice daily (≈ 2.5 mg BID for a 10 kg infant) is the recommended oral antihistamine for a 20‑month‑old child; it is one of only two antihistamines with documented safety data and FDA approval for children under 2 years. 1
Cetirizine and loratadine are the only antihistamines that have FDA approval for use in children younger than 5 years. 1
Loratadine may be used as an alternative (5 mg once daily for children 2‑5 years); for a 20‑month‑old infant dosing must be individualized by a physician. [1][2]

Liquid formulations are strongly preferred for infants because they are easier to administer and provide better absorption. 2
Sedation is uncommon at the recommended cetirizine dose, but clinicians should monitor for it when higher‑than‑usual doses are used. 1

Intranasal corticosteroids are the most effective medication class for controlling all symptoms of allergic rhinitis in children < 2 years, supported by high‑quality evidence. 1
When used at recommended doses, intranasal corticosteroids are not associated with clinically significant systemic side effects. 1
Guideline recommendation: Use intranasal corticosteroids as first‑line therapy; cetirizine may be added as a second‑line or adjunctive agent. 1

First‑generation antihistamines (diphenhydramine, hydroxyzine) should never be prescribed for routine allergic symptoms in children < 6 years because of significant safety concerns. [1][2]
Between 1969 and 2006, 69 deaths in children < 6 years were linked to antihistamine exposure; 41 occurred in children < 2 years, with diphenhydramine responsible for 33 of those deaths. [1][2]
The FDA and the American Academy of Pediatrics explicitly recommend against using over‑the‑counter cough‑and‑cold products that contain first‑generation antihistamines in children < 6 years. [1][2]
Intranasal antihistamines (azelastine, olopatadine) are approved only for children ≥ 12 years and should not be used in infants. 3
Oral decongestants (pseudoephedrine, phenylephrine) must be used with extreme caution in infants and young children; they have been associated with severe neuropsychiatric effects and death. 3

Using antihistamines “to make a child sleepy” is contraindicated per FDA labeling. 2
OTC cough‑and‑cold combination products should be avoided in children < 6 years because of overdose risk. 2

All statements are derived from cited evidence and reflect current FDA and professional society recommendations.